IL1R1 and systemic-onset juvenile idiopathic arthritis: Furthermore, the development of anti-IL-1R1 monoclonal antibodies for rheumatoid arthritis, Still’s disease, and osteoarthritis underscores the potential for targeting this pathway in IBD [95,96].